Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBT Avalon GloboCare	$2.09 +5.0%	$2.53	$1.87 ▼ $11.66	$3.77M	-0.02	1.43 million shs	28,973 shs
BPTH Bio-Path	$0.12	$0.16	$0.09 ▼ $3.39	$997K	-0.06	183,391 shs	4,504 shs
DRMA Dermata Therapeutics	$5.33 -1.5%	$6.56	$5.09 ▼ $24.90	$3.69M	0.56	29,118 shs	6,768 shs
SLXN Silexion Therapeutics	$6.80 -0.3%	$11.00	$6.51 ▼ $256.50	$3.95M	0.08	148,714 shs	27,799 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBT Avalon GloboCare	-1.97%	-11.56%	-14.22%	-48.18%	-61.88%
BPTH Bio-Path	+10.09%	-14.29%	-23.57%	-31.82%	-91.89%
DRMA Dermata Therapeutics	-4.08%	-16.38%	-22.15%	-29.56%	-73.22%
SLXN Silexion Therapeutics	-2.88%	-6.69%	-44.19%	-53.30%	+690,499,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBT Avalon GloboCare	1.1566 of 5 stars	0.0	2.0	4.3	2.2	1.7	0.0
BPTH Bio-Path	1.4824 of 5 stars	0.0	5.0	0.0	2.5	0.0	1.3
DRMA Dermata Therapeutics	3.3364 of 5 stars	3.5	5.0	0.0	3.5	0.8	0.6
SLXN Silexion Therapeutics	1.351 of 5 stars	3.5	0.0	0.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBT Avalon GloboCare	0.00	N/A	N/A	N/A
BPTH Bio-Path	0.00	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.00	Buy	$10.00	87.62% Upside
SLXN Silexion Therapeutics	3.00	Buy	$75.00	1,002.94% Upside

Current Analyst Ratings Breakdown

Latest BPTH, ALBT, SLXN, and DRMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $30.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBT Avalon GloboCare	$1.33M	2.97	N/A	N/A	($10.27) per share	-0.20
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$8.24 per share	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	$0.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBT Avalon GloboCare	-$7.90M	-$19.96	N/A	∞	N/A	-1,451.94%	N/A	-75.12%	N/A
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	8/21/2025 (Estimated)
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-214.98%	-153.76%	N/A
SLXN Silexion Therapeutics	-$16.44M	N/A	0.00	∞	N/A	N/A	N/A	-355.74%	9/4/2025 (Estimated)

Latest BPTH, ALBT, SLXN, and DRMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALBT Avalon GloboCare	N/A	-$2.02	N/A	-$6.22	N/A	$0.35 million
8/13/2025	Q2 2025	DRMA Dermata Therapeutics	-$2.90	-$1.66	+$1.24	-$1.66	N/A	N/A
8/12/2025	Q2 2025	SLXN Silexion Therapeutics	-$3.15	-$4.32	-$1.17	-$4.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBT Avalon GloboCare	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBT Avalon GloboCare	N/A	0.06	0.19
BPTH Bio-Path	N/A	0.86	0.86
DRMA Dermata Therapeutics	N/A	6.47	6.47
SLXN Silexion Therapeutics	26.58	2.44	2.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBT Avalon GloboCare	1.42%
BPTH Bio-Path	5.74%
DRMA Dermata Therapeutics	8.67%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
ALBT Avalon GloboCare	37.30%
BPTH Bio-Path	0.72%
DRMA Dermata Therapeutics	18.50%
SLXN Silexion Therapeutics	6.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBT Avalon GloboCare	5	1.89 million	1.19 million	Not Optionable
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
DRMA Dermata Therapeutics	8	680,000	556,000	Not Optionable
SLXN Silexion Therapeutics	N/A	580,000	545,000	N/A

BPTH, ALBT, SLXN, and DRMA Headlines

Recent News About These Companies

Silexion Therapeutics Increases Authorized Share Capital

August 19 at 10:31 AM | tipranks.com

Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025 | finanznachrichten.de

Silexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven Cancers

August 12, 2025 | quiverquant.comQ

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | globenewswire.com

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

July 31, 2025 | globenewswire.com

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

July 31, 2025 | globenewswire.com

Silexion Therapeutics Holds Annual General Meeting

July 17, 2025 | theglobeandmail.com

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

July 16, 2025 | globenewswire.com

Silexion Therapeutics Corp. Reports Positive Preclinical Data for ...

July 11, 2025 | nasdaq.com

Silexion Therapeutics Announces Positive Results in Preclinical Study ...

July 11, 2025 | morningstar.comM

Silexion Therapeutics receives Nasdaq panel approval for continued listing

July 9, 2025 | uk.investing.com

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

July 9, 2025 | globenewswire.com

Silexion Therapeutics announces preclinical results on SIL204

May 30, 2025 | finance.yahoo.com

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

May 30, 2025 | msn.com

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

May 29, 2025 | finance.yahoo.com

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers

May 23, 2025 | nasdaq.com

Silexion Therapeutics Receives Nasdaq Delisting Notice

May 23, 2025 | tipranks.com

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025 | globenewswire.com

Silexion Therapeutics Corporation Registered Shs

May 22, 2025 | markets.businessinsider.com

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

May 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH, ALBT, SLXN, and DRMA Company Descriptions

Avalon GloboCare NASDAQ:ALBT

$2.09 +0.10 (+5.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 +0.02 (+0.72%)

As of 07:31 PM Eastern

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Bio-Path NASDAQ:BPTH

$0.12 0.00 (0.00%)

As of 10:56 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Dermata Therapeutics NASDAQ:DRMA

$5.33 -0.08 (-1.48%)

Closing price 03:57 PM Eastern

Extended Trading

$5.62 +0.30 (+5.53%)

As of 07:59 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Silexion Therapeutics NASDAQ:SLXN

$6.80 -0.02 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.79 -0.01 (-0.15%)

As of 05:06 PM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time